

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – November 8, 2017 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. October 4, 2017 DUR Minutes – Vote
- B. October 4, 2017 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Nichols, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/2017 Fall Pipeline Update – See Appendix B

- A. Medication Coverage Activity for October 2017
- B. Pharmacy Help Desk Activity for October 2017
- C. 2017 Fall Pipeline Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Kevzara[®] (Sarilumab), Siliq[™] (Brodalumab), Tremfya[™] (Guselkumab), Cyltezo[™] (Adalimumab-adbm), and Renflexis[™] (Infliximab-abda)

– See Appendix C

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Blincyto[®] (Blinatumomab), Besponsa[®] (Inotuzumab Ozogamicin), Bosulif[®] (Bosutinib), Gleevec[®] (Imatinib), Iclusig[®] (Ponatinib), Kymriah[™] (Tisagenlecleucel), Synribo[®] (Omacetaxine), Sprycel[®] (Dasatinib), and Tassigna[®] (Nilotinib)

– See Appendix D

- A. Introduction
- B. Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Bavencio[®] (Avelumab) and Update Skin Cancer Medications Prior Authorization Criteria – See Appendix E

- A. Introduction
- B. Recommendations

Items to be presented by Dr. Nichols, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Haegarda[®] [C1 Esterase Inhibitor (Human)]

– See Appendix F

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nichols, Dr. Muchmore, Chairman:

**9. Action Item – Vote to Prior Authorize Axid[®] (Nizatidine Capsules and Solution), Tagamet[®] (Cimetidine Tablets), and Yosprala[™] (Aspirin/Omeprazole Delayed-Release Tablets)
– See Appendix G**

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Trulance[™] (Plecanatide), Xermelo[™] (Telotristat Ethyl), Symproic[®] (Naldemedine), and Motofen[®] (Difenoxin/Atropine) – See Appendix H

A. Introduction

B. Cost Comparison: Constipation Medications

C. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**11. Action Item – Vote to Prior Authorize MiCort[™] HC (Hydrocortisone Acetate 2.5% Cream) and Update the Topical Corticosteroids Product Based Prior Authorization Tier Chart and Criteria
– See Appendix I**

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**12. Action Item – Vote to Prior Authorize Noctiva[™] (Desmopressin Acetate Nasal Spray)
– See Appendix J**

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

13. Action Item – Vote to Prior Authorize Sprix[®] (Ketorolac Tromethamine Nasal Spray) and Cataflam[®] (Diclofenac Potassium Tablets) – See Appendix K

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

14. Action Item – Vote to Prior Authorize Promacta[®] (Eltrombopag) and Update Prior Authorization Criteria for Nplate[®] (Romiplostim) – See Appendix L

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

15. Action Item – Vote to Prior Authorize Odactra[™] (House Dust Mite Allergen Extract) and Update Allergen Immunotherapy Prior Authorization Criteria – See Appendix M

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

16. Action Item – Annual Review of Nuedexta[®] (Dextromethorphan/Quinidine) – See Appendix N

A. Introduction

B. Current Prior Authorization Criteria

C. Utilization of Nuedexta[®] (Dextromethorphan/Quinidine)

D. Prior Authorization of Nuedexta[®] (Dextromethorphan/Quinidine)

E. Market News and Updates

F. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**17. Action Item – Annual Review of Orkambi[®] (Lumacaftor/Ivacaftor) and Kalydeco[®] (Ivacaftor)
– See Appendix O**

A. Current Prior Authorization Criteria

- B. Utilization of Orkambi® and Kalydeco®
- C. Prior Authorization of Orkambi® and Kalydeco®
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Orkambi® and Kalydeco®

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

18. Action Item – Annual Review of Iron Chelating Agents and Vote to Prior Authorize Jadenu® Sprinkle (Deferasirox Oral Granules) – See Appendix P

- A. Current Prior Authorization Criteria
- B. Utilization of Iron Chelating Agents
- C. Prior Authorization of Iron Chelating Agents
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Iron Chelating Agents

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

19. Annual Review of Hepatitis C Medications and 30-Day Notice to Prior Authorize Mavyret™ (Glecaprevir/Pibrentasvir) and Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) – See Appendix Q

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Hepatitis C Medications
- D. Prior Authorization of Hepatitis C Medications
- E. Market News and Updates
- F. Regimen Comparison
- G. Mavyret™ (Glecaprevir/Pibrentasvir) Product Summary
- H. Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) Product Summary
- I. College of Pharmacy Recommendations
- J. Utilization Details of Hepatitis C Medications

Items to be presented by Dr. Nichols, Dr. Muchmore, Chairman:

20. Annual Review of Various Systemic Antibiotic Medications and 30-Day Notice to Prior Authorize Baxdela™ (Delafloxacin Injection and Tablets), Ofloxacin 300mg Tablets, Minolira™ (Minocycline Extended-Release Tablets), Solosec™ (Secnidazole Oral Granules), and Vabomere™ (Meropenem/Vaborbactam Injection) – See Appendix R

- A. Current Prior Authorization Criteria
- B. Utilization of Various Systemic Antibiotic Medications
- C. Prior Authorization of Various Systemic Antibiotic Medications
- D. Market News and Updates
- E. Baxdela™ (Delafloxacin) Product Summary
- F. Minolira™ (Minocycline Extended-Release Tablets) Product Summary
- G. Solosec™ (Secnidazole Oral Granules) Product Summary
- H. Vabomere™ (Meropenem/Vaborbactam Injection) Product Summary
- I. Cost Comparison
- J. College of Pharmacy Recommendations
- K. Utilization Details of Various Systemic Antibiotic Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

21. Annual Review of Gout Medications and 30-Day Notice to Prior Authorize Duzallo® (Lesinurad/Allopurinol) – See Appendix S

- A. Current Prior Authorization Criteria
- B. Utilization of Gout Medications
- C. Prior Authorization of Gout Medications
- D. Market News and Updates
- E. Duzallo® (Lesinurad/Allopurinol) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Gout Medications

Non-Presentation; Questions Only:

22. Annual Review of Pancreatic Enzymes – See Appendix T

- A. Current Prior Authorization Criteria
- B. Utilization of Pancreatic Enzymes
- C. Prior Authorization of Pancreatic Enzymes
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Pancreatic Enzymes

Non-Presentation; Questions Only:

23. Industry News and Updates – See Appendix U

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

24. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix V

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

25. Future Business* (Upcoming Product and Class Reviews)

- A. Maintenance Asthma and Chronic Obstructive Pulmonary Disease (COPD) Medications
- B. Phosphate Binding Medications
- C. Duchenne Muscular Dystrophy Medications
- D. Ocular Allergy Medications
- E. Anti-Emetic Medications

**Future business subject to change.*

26. Adjournment